News

FDA approves powerful HIV drug that nearly eliminated spread in clinical trials
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
FDA Approves ‘Breakthough’ Drug to Prevent HIV
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
NBC News on MSN6h
FDA approves powerful new HIV drug
The Food and Drug Administration approved a new, highly effective HIV-prevention medication. The drug nearly eliminated HIV’s spread among people given an injection twice a year in clinical trials.
Mother Jones4h
FDA Approves “Breakthrough” HIV Drug
On Wednesday, the Food and Drug Administration approved a highly effective, injectable drug to help prevent the transmission ...
WLRN1h
HIV prevention drug hailed as a 'breakthrough' gets FDA approval
A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...
The FDA Approves Powerful HIV Prevention Drug
But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.
Applied Clinical Trials Online16h
The Future of Cardiac Safety: How Wearable ECGs Enhance Patient Monitoring in Drug Trials
As wearable ECG technology advances, cardiac safety studies in clinical trials are evolving to capture richer, continuous ...
STAT7h
HIV protection with just two shots a year: FDA approves Gilead drug
A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...
PharmTech11h
FDA Voucher Program Provides Shorter Drug Application Review Time
The Commissioner’s National Priority Voucher can be used by drug developers to participate in a novel priority program for ...
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Market View 2025 - Commercial Sponsors Have Led Clinical Trials, With Armagen Heading Four Trials
Explore the competitive landscape of Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. In 2024, over 1,740 cases were diagnosed across 16 count ...